secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-276209
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Q3 net loss $4.3M; cash $13.7M; tab-cel BLA PDUFA Jan 10, 2026
--------------------------------------------------------------------

- Cash and equivalents $13.7M as of Sep 30, 2025, down from $22.3M at Jun 30.
- Net loss of $4.3M ($0.32 per share) vs. $21.9M loss a year ago.
- Total revenues $3.5M, down from $40.2M in Q3 2024 due to deferred revenue recognition.
- Workforce reduced ~29% in Oct 2025; ~15 employees now retained.
- FDA accepted tab-cel BLA with Priority Review; $40M milestone due from Pierre Fabre upon approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/0001193125-25-276209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/d66575d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-276209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer